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Background
Natalizumab is an approved drug used in relapsing and
aggressive Multiple Sclerosis (MS). This is a monoclonal
anti-integrin antibody that decreases the transmigration of
immune cells through the blood-brain-barrier in animal
models of MS. In human, the number of T cells in the
CSF is dramatically decreased while the number of circu-
lating lymphocytes usually increases. We hypothesized
that in patients treated with natalizumab, the infiltration
of T cells in the brain parenchyma decreases. These cells
may accumulate in the blood of the patients and thus alter
the T cell repertoire.
Objectives
We assessed whether the treatment by natalizumab
resulted in the apparition of Vb clonal selections one year
after the beginning of the treatment.
Methods
The T Cell Receptor (TCR) repertoire was investigated by
the analysis of the CDR3 length distribution of the b
chain. The blood of MS patients was sampled just before
the beginning of Natalizumab, and six months and one
year after. CDR3 spectratyping was performed at those
three different time points. Each profile was assessed as
“gaussian”, “altered polyclonal”, “altered oligoclonal” or
“altered monoclonal” and the alterations observed were
compared.
Results
Four relapsing-remitting MS patients were included in
this study. At baseline, we observed more alterations in
the CD8
+ compartment compared with the CD4
+ one.
One year after the beginning of the treatment, the global
percentage of alterations did not increase for CD4
+ or
CD8
+ cells. However, for three patients, we observed the
apparition of private Vb clonal selections.
Discussion/perspectives
Given the mechanisms of action of natalizumab, one may
hypothesize that the clonal cells observed in the blood
after one year of treatment could have a major role in the
pathophysiological process in the disease. We now plan to
analyze the phenotype and the reactivity of these clones
against myelin antigens.
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